Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | CASP1 | P29466 | 1/20 | 0.69 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.69 |
| ▸ | CASP7 | P55210 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20612448 | 0.85 | GAA (0.54) | FLT3LMNAKDM4EALDH1A1GAA | |
| SCHEMBL31060249 | 0.85 | FLT3 (1.00) | FLT3LMNAKDM4EALDH1A1GAA | |
| SCHEMBL6021894 | 0.83 | FLT3 (0.76) | FLT3LMNAKDM4EALDH1A1GAA | |
| SCHEMBL3487776 | 0.83 | FLT3 (0.76) | FLT3LMNAKDM4EALDH1A1GAA | |
| SCHEMBL15623111 | 0.81 | ALDH1A1 (0.69) | FLT3LMNAKDM4EALDH1A1GAA | |
| SCHEMBL11684788 | 0.81 | ALDH1A1 (0.69) | FLT3LMNAKDM4EALDH1A1GAA | |
| SCHEMBL30402838 | 0.81 | KDM4E (1.00) | FLT3LMNAKDM4EALDH1A1GAA | |
| SCHEMBL1390692 | 0.81 | KDM4E (1.00) | FLT3LMNAKDM4EALDH1A1GAA | |
| SCHEMBL20136031 | 0.81 | LMNA (0.62) | FLT3LMNAKDM4EALDH1A1GAA | |
| SCHEMBL211674 | 0.81 | FLT3 (0.67) | FLT3LMNAKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014087428-A1 | PROCESS FOR PREPARATION OF VILAZODONE AND INTERMEDIATES THEREOF | GLENMARK PHARMACEUTICALS LIMITED; GLENMARK GENERICS LIMITED (IN) | 2014-06-12 | — | — | WO | disclosed |
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-7432288-B2 | Pyrrole-2,5-dione derivatives as Liver X receptor modulators | ASTRAZENECA AB (SE) | 2008-10-07 | — | — | US | disclosed |
| EP-1646626-B1 | PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| US-20060235015-A1 | Pyrrole-2,5-dione derivatives as liver x receptor modulators | ASTRAZENECA AB (SE) | 2006-10-19 | — | — | US | disclosed |
| EP-1646626-A1 | PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005005417-A1 | PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | NR1H2, NR1H3, NR1I2 | FLT3 3024/4885LMNA 3519/4885KDM4E 4430/4885 |
| US-20060235015-A1 | Pyrrole-2,5-dione derivatives as liver x receptor modulators | NR1H2, NR1H3, SREBF2 | FLT3 2473/4885LMNA 2498/4885KDM4E 3260/4885 |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | FLT3 2999/4885LMNA 3647/4885KDM4E 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.